Literature DB >> 2449840

Regulation of the expression of class II genes of the human major histocompatibility complex in tumor cells.

R Gambari1, R Barbieri, R Piva, R Tecce, P B Fisher, P Giacomini, P G Natali.   

Abstract

The control of expression of human class II MHC genes has been studied in lymphoid and melanoma cells. Specific unmethylation of all restriction sites nearby the promoter regions has been detected in all cell lines and tissues studied, irrespective of their ability to express class II MHC products. The main functional role of DNA methylation appears, on the contrary, to be the regulation of a fraction of the nucleotide polymorphism of class II MHC genes. Constitutive expression of these genes can be modified by recombinant IFN-gamma and by the demethylating agent 5-azacytidine. Both the modifiers differentially regulate the levels of class II MHC and invariant chain products. In melanoma cells IFN-gamma derepresses transcription of a 1.2-Kb HLA-DR alpha mRNA, but does not affect the levels of a 0.8-Kb HLA-DR alpha specific mRNA. These molecular changes are triggered by IFN-gamma through a protein-synthesis-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2449840     DOI: 10.1111/j.1749-6632.1987.tb36258.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

1.  Tissue-specific expression of the HLA-DRA gene in transgenic mice.

Authors:  P Giacomini; A Ciucci; M R Nicotra; C Nastruzzi; G Feriotto; E Appella; R Gambari; L Pozzi; P G Natali
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

2.  Sequencing of an upstream region of the human HLA-DRA gene containing X' and Y' boxes.

Authors:  G Feriotto; C Mischiati; N Bianchi; C Rutigliano; P Giacomini; R Gambari
Journal:  Nucleic Acids Res       Date:  1995-05-25       Impact factor: 16.971

3.  Hypomethylation of the human HLA-DR alpha gene in breast carcinomas and autologous metastases.

Authors:  R Barbieri; A P Rimondi; D Buzzoni; L Luppi; C Nastruzzi; P Orlando; R Gambari
Journal:  Clin Exp Metastasis       Date:  1989 Jul-Aug       Impact factor: 5.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.